SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease
Use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) is associated with a substantially lower risk for dialysis and cardiovascular disease in patients with type 2 diabetes (T2D) and ...